Therapeutic efficacy of ranitidine bismuth citrate with clarithromycin for seven days in the eradication of Helicobacter pylori in Brazilian peptic ulcer patients.
BACKGROUND
The curative treatment of peptic ulcer is made available nowadays through the eradication of the bacterium Helicobacter pylori, which is associated with it, but the best therapeutic regimen is yet to be determined.


OBJECTIVE
To assess the efficacy of a therapeutic regimen with 400 mg ranitidine bismuth citrate associated with 500 mg clarithromycin given twice a day for seven days in a cohort of Brazilian patients with peptic ulcer.


METHODS
Cross-sectional study.


METHODS
Tertiary-care hospital.


METHODS
One hundred and twenty nine outpatients, with active or healed peptic ulcers infected by Helicobacter pylori, diagnosed via endoscopy with confirmation via the urease test and histological examination, who had never undergone a regimen for the eradication of the bacterium.


METHODS
Administration of 400 mg ranitidine-bismuth and 500 mg clarithromycin twice a day, for seven days.


METHODS
Efficacy of the treatment, with a check on the cure done via another endoscopy eight weeks after drug administration. The eradication of the bacterium was determined via the urease test and histological examination. Patients who were negative for both were considered to be cured.


RESULTS
Eight patients failed to complete the study. The eradication rate according to intention to treat was 81% (104/129) and per protocol was 86% (104/121).


CONCLUSIONS
The bismuth ranitidine compound associated with clarithromycin used for one week was shown to be a simple, effective and well-tolerated therapeutic regimen for the eradication of Helicobacter pylori.
Departamento de Gastroenterologia Clínica, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. jaimeeisig@hotmail.com
Jaime Natan
JN
Eisig
Fernando Marcuz
FM
Silva
Cláudio
C
Hashimoto
Ethel Zimberg
EZ
Chehter
Antonio Atilio
AA
Laudanna
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001729:Bismuth / Q000008:administration & dosage*; D001938:Brazil; D017291:Clarithromycin / Q000008:administration & dosage*; D003430:Cross-Sectional Studies; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology; D011899:Ranitidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; C073340:ranitidine bismuth citrate; D011899:Ranitidine; D017291:Clarithromycin; D001729:Bismuth